Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer

References

• YangJCWuYLSchulerMAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol20151614115125589191
   PubMed Web of Science ®Google Scholar
• de VisserKEEichtenACoussensLMParadoxical roles of the immune system during cancer developmentNat Rev Cancer20066243716397525
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med20123662455246522658128
   PubMedGoogle Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol20111273574221783417
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med200535312313216014882
   PubMed Web of Science ®Google Scholar
• SequistLVMartinsRGSpigelDFirst-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsJ Clin Oncol2008262442244918458038
   PubMed Web of Science ®Google Scholar
• ZielinskiCKnappSMascauxCHirschFRationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancerAnn Oncol2013241170117923393121
   PubMed Web of Science ®Google Scholar
• FordePMReissKAZeidanAMBrahmerJRWhat lies within: novel strategies in immunotherapy for non-small cell lung cancerOncologist2013181203121324105749
   PubMedGoogle Scholar
• AertsJGLievenseLAHoogstedenHCHegmansJPImmunotherapy prospects in the treatment of lung cancer and mesotheliomaTransl Lung Cancer Res20143344525806279
   PubMedGoogle Scholar
• KormanAJPeggsKSAllisonJPCheckpoint blockade in cancer immunotherapyAdv Immunol20069029733916730267
   PubMed Web of Science ®Google Scholar
• McDermottDFAtkinsMBPD-1 as a potential target in cancer therapyCancer Med2013266267324403232
   PubMed Web of Science ®Google Scholar
• AzumaKOtaKKawaharaAAssociation of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancerAnn Oncol2014251935194025009014
   PubMed Web of Science ®Google Scholar
• ChenNFangWZhanJUpregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutationJ Thorac Oncol20151091092325658629
   PubMed Web of Science ®Google Scholar
• TaubeJMKleinABrahmerJRAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyClin Cancer Res2014205064507424714771
   PubMed Web of Science ®Google Scholar
• BrooksMBErlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-alpha mediated inflammatory diseasesOncologist201318e3e523355622
   PubMed Web of Science ®Google Scholar
• MohamedMKRamalingamSLinYGoodingWBelaniCPSkin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancerAnn Oncol20051678078515728108
   PubMed Web of Science ®Google Scholar
• GalluzziLSenovillaLZitvogelLKroemerGThe secret ally: immunostimulation by anticancer drugsNat Rev Drug Discov20121121523322301798
   PubMed Web of Science ®Google Scholar
• LodoenMOgasawaraKHamermanJANKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene moleculesJ Exp Med20031971245125312756263
   PubMedGoogle Scholar
• MillerJSThe biology of natural killer cells in cancer, infection, and pregnancyExp Hematol2001291157116811602317
   PubMed Web of Science ®Google Scholar
• RauletDHGuerraNOncogenic stress sensed by the immune system: role of natural killer cell receptorsNat Rev Immunol2009956858019629084
   PubMed Web of Science ®Google Scholar
• HeSYinTLiDEnhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulationJ Transl Med20131118623937717
   PubMed Web of Science ®Google Scholar
• LeemhuisTWellsSScheffoldCEdingerMNegrinRSA phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphomaBiol Blood Marrow Transplant20051118118715744236
   PubMed Web of Science ®Google Scholar
• LuoQGuYZhengWErlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathwayToxicol Appl Pharmacol201125113013621195724
   PubMedGoogle Scholar
• GollobJAWilhelmSCarterCKelleySLRole of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathwaySemin Oncol20063339240616890795
   PubMed Web of Science ®Google Scholar
• Fresno VaraJACasadoEde CastroJCejasPBelda-IniestaCGonzález-BarónMPI3K/Akt signalling pathway and cancerCancer Treat Rev20043019320415023437
   PubMed Web of Science ®Google Scholar
• OnoMKuwanoMMolecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugsClin Cancer Res2006127242725117189395
   PubMed Web of Science ®Google Scholar
• O’CallaghanDSO’DonnellDO’ConnellFO’ByrneKJThe role of inflammation in the pathogenesis of non-small cell lung cancerJ Thorac Oncol201052024203621155185
   PubMed Web of Science ®Google Scholar
• GrivennikovSIKarinMInflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stageAnn Rheum Dis201170Suppl 1i104i10821339211
   PubMedGoogle Scholar
• BoehmUKlampTGrootMHowardJCCellular responses to interferon-gammaAnnu Rev Immunol1997157497959143706
   PubMed Web of Science ®Google Scholar
• HodgeDRHurtEMFarrarWLThe role of IL-6 and STAT3 in inflammation and cancerEur J Cancer2005412502201216199153
   PubMed Web of Science ®Google Scholar
• KaplanDHShankaranVDigheASDemonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent miceProc Natl Acad Sci U S A199895755675619636188
   PubMed Web of Science ®Google Scholar
• LukaszewiczMMroczkoBSzmitkowskiMClinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer diseasePol Arch Med Wewn200711724725118030875
   PubMedGoogle Scholar
• SullivanNJSasserAKAxelAEInterleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cellsOncogene2009282940294719581928
   PubMed Web of Science ®Google Scholar
• ColomiereMWardACRileyCCross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial- mesenchymal transition in ovarian carcinomasBr J Cancer200910013414419088723
   PubMed Web of Science ®Google Scholar
• ThomsonSBuckEPettiFEpithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibitionCancer Res2005659455946216230409
   PubMed Web of Science ®Google Scholar
• YaoZFenoglioSGaoDCTGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancerProc Natl Acad Sci U S A2010107155351554020713723
   PubMed Web of Science ®Google Scholar
• SongXYZhouSJXiaoNResearch on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancerAsian Pac J Cancer Prev2013144765476824083740
   PubMedGoogle Scholar
• SongurNKuruBKalkanFOzdilekcanCCakmakHHizelNSerum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancerTumori20049019620015237582
   PubMed Web of Science ®Google Scholar
• ChangCHHsiaoCFYehYMCirculating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapyInt J Cancer20131321977198523034889
   PubMed Web of Science ®Google Scholar
• HaradaDTakigawaNKiuraKThe role of STAT3 in non-small cell lung cancerCancers (Basel)2014670872224675568
   PubMed Web of Science ®Google Scholar
• GuoYXuFLuTDuanZZhangZInterleukin-6 signaling pathway in targeted therapy for cancerCancer Treat Rev20123890491022651903
   PubMed Web of Science ®Google Scholar
• TrikhaMCorringhamRKleinBRossiJFTargeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidenceClin Cancer Res200394653466514581334
   PubMed Web of Science ®Google Scholar
• PostowMACallahanMKWolchokJDImmune checkpoint blockade in cancer therapyJ Clin Oncol2015331974198225605845
   PubMed Web of Science ®Google Scholar
• CerwenkaAFalkCSWatzlCNK cells from basic research to cancer therapyEur J Immunol2007371161116417447232
   PubMedGoogle Scholar
• VannemanMDranoffGCombining immunotherapy and targeted therapies in cancer treatmentNat Rev Cancer20121223725122437869
   PubMed Web of Science ®Google Scholar